{"id":"docetaxel-polymeric-micelles-for-injection","brandName":"Docetaxel Polymeric Micelles for Injection","genericName":"Docetaxel Polymeric Micelles for Injection","companyId":"jiangsu-simcere-pharmaceutical-co-ltd","companyName":"Jiangsu Simcere Pharmaceutical Co., Ltd.","phase":"phase_2","status":"active","modality":"Small molecule","aliases":[],"developmentCodes":[],"firstApprovalDate":null,"firstApprovalCountry":null,"aiSummary":"Docetaxel Polymeric Micelles for Injection, developed by Jiangsu Simcere Pharmaceutical Co., Ltd., is a novel formulation of docetaxel designed to improve its pharmacokinetics and safety profile. Currently in Phase I and Phase II trials, it targets advanced solid tumors and malignant ascites. The drug aims to enhance the therapeutic index of docetaxel by reducing systemic toxicity while maintaining or improving efficacy.","enrichmentLevel":3,"visitCount":0,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"This leads to cell cycle arrest at the G2/M phase and apoptosis in cancer cells.","oneSentence":"Docetaxel inhibits microtubule dynamics by stabilizing microtubules and preventing their depolymerization.","_ai_confidence":"high"},"administration":{},"safety":{"commonSideEffects":[{"rate":"43%","effect":"Neutropenia"},{"rate":"34%","effect":"Anemia"},{"rate":"31%","effect":"Fatigue"}]},"trials":[],"indications":{"approved":[{"name":"Non-small cell lung cancer"},{"name":"Breast cancer"},{"name":"Prostate cancer"}]},"commercial":null,"patents":[],"timeline":[],"rwe":[],"competitors":[],"ownershipHistory":[],"trialDetails":[],"genericFilers":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"labelChanges":[],"nice":null,"revenue":null,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":false,"score":3}}